Figure 4.
Safety and tolerability of ibrutinib over time. Rate of grade ≥3 AEs, discontinuations due to AEs, and dose reductions over different periods of time. AE, adverse events.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.